US2023147035A1PendingUtilityA1
Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
Est. expiryMay 30, 2037(~10.8 yrs left)· nominal 20-yr term from priority
C07B 2200/05C07B 59/004A61P 35/00A61P 13/08A61K 51/0497A61K 51/0482A61K 51/0402C07D 401/12C07D 257/02C07F 7/24C07B 59/002C07F 5/003
63
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.
Claims
exact text as granted — not AI-modifiedThat which is claimed:
1 . A compound of Formula (I):
wherein:
Z is tetrazole or CO 2 Q;
Q is H or a protecting group;
m is an integer selected from the group consisting of 1, 2, 3, 4, and 5;
R is independently H or —CH 2 —R 1 ;
R 1 is selected from the group consisting of substituted aryl, substituted pyridine, and unsubstituted isoquinoline;
L is a linker selected from the group consisting of C 1 -C 6 alkylene and C 3 -C 6 cycloalkylene, and arylene;
W is selected from the group consisting of —NR 2 —(C═O)—, —NR 2 —(C═S)—, —(C═O)—NR 2 —, and —(C═S)—NR 2 —; wherein each occurrence of L and W can be the same or different;
R 2 is H or a C 1 -C 4 alkyl;
n is an integer selected from the group consisting of 1, 2, and 3;
Ch is a chelating agent that can comprise a metal or a radiometal;
and pharmaceutically acceptable salts thereof.
2 . The compound of claim 1 , wherein R 1 is selected from the group consisting of:
wherein X is independently Br or I.
3 . The compound of claim 1 , wherein the chelating agent is selected from the group consisting of:
4 . The compound of claim 1 , wherein the metal chelating agent comprises a metal selected from the group consisting of: Y, Lu, Tc, Zr, In, Sm, Re, Cu, Pb, Ac, Bi, Al, Ga, Re, Ho and Sc.
5 . The compound of claim 4 , wherein the metal is a radiometal and is selected from the group consisting of: 68 Ga, 64Cu, 86 Y, 90 Y, 89 Zr, 111 In, 99m Tc, 177 Lu, 153 Sm, 186 Re, 188 Re, 67 Cu, 212 Pb, 225 Ac, 213 Bi, 212 Bi, 212 Pb, 67 Ga, 203 Pb, 47 Sc, and 166 Ho.
6 . The compound of claim 1 , wherein the compound of Formula (I) is selected from the group consisting of:
7 . A method for treating one or more PSMA expressing tumors or cells, the method comprising contacting the one or more PSMA expressing tumors or cells with an effective amount of a compound of formula (I), the compound of formula (I) comprising:
wherein:
Z is tetrazole or CO 2 Q;
Q is H or a protecting group;
m is an integer selected from the group consisting of 1, 2, 3, 4, and 5;
R is independently H or —CH 2 —R 1 ;
R 1 is selected from the group consisting of substituted aryl, substituted pyridine, and unsubstituted isoquinoline;
L is a linker selected from the group consisting of C 1 -C 6 alkylene and C 3 -C 6 cycloalkylene, and arylene;
W is selected from the group consisting of —NR 2 —(C═O)—, —NR 2 —(C═S)—, —(C═O)—NR 2 —, and —(C═S)—NR 2 —; wherein each occurrence of L and W can be the same or different;
R 2 is H or a C 1 -C 4 alkyl;
n is an integer selected from the group consisting of 1, 2, and 3;
Ch is a chelating agent that comprises a radiometal suitable for radiotherapy;
and pharmaceutically acceptable salts thereof.
8 . The method of claim 7 , wherein R 1 is selected from the group consisting of:
wherein X is independently Br or I.
9 . The method of claim 7 , wherein the chelating agent is selected from the group consisting of:
10 . The method of claim 7 , wherein the radiometal is selected from the group consisting of: 90Y 177Lu, 211 At 111 In, 153 Sm, 186 Re, 188 Re, 67 Cu, 212 Pb, 225 Ac, 213 Bi, 212 Bi, 212 Pb, and 67 Ga.
11 . The method of claim 7 , wherein the compound is selected from the group consisting of:
12 . The method of claim 7 , wherein the one or more PSMA-expressing tumor or cell is selected from the group consisting of: a prostate tumor or cell, a metastasized prostate tumor or cell, a lung tumor or cell, a renal tumor or cell, a glioblastoma, a pancreatic tumor or cell, a bladder tumor or cell, a sarcoma, a melanoma, a breast tumor or cell, a colon tumor or cell, a germ cell, a pheochromocytoma, an esophageal tumor or cell, a stomach tumor or cell, and combinations thereof.
13 . The method of claim 7 , wherein the one or more PSMA-expressing tumor or cell is a prostate tumor or cell.
14 . The method of claim 7 , wherein the one or more PSMA-expressing tumor or cell is in vitro, in vivo, or ex vivo.
15 . The method of claim 7 , wherein the one or more PSMA-expressing tumor or cell is present in a subject.
16 . The method of claim 15 , wherein the subject is human.
17 . The method of claim 7 , wherein the method results in inhibition of the tumor growth.
18 . The compound of claim 1 , wherein the compound of formula (I) is selected from the group consisting of:
wherein: X is H or 4-benzylbromine;
M is selected from the group consisting of 177 Lu, 225 Ac, 213 Bi, and 203 Pb.
19 . The method of claim 7 , wherein the compound of formula (I) is selected from the group consisting of:
wherein: X is H or 4-benzylbromine; and
M is selected from the group consisting of 177 Lu, 225 Ac, 213 Bi, and 203 Pb.Join the waitlist — get patent alerts
Track US2023147035A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.